S everal themes have emerged during recent years in the psychopharmacology of depression literature. Not only is depression a recurrent condition, but its tendency to become increasingly severe and refractory to treatment over time has led investigators to argue for longer duration of continuation and maintenance therapies. This trend parallels reports that the "new medications," especially selective serotonin reuptake inhibitors (SSRIs), offer significant benefits in terms of compliance and safety in overdose compared with their forerunners such as tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors. Despite considerably higher "up-front" costs, pharmacoeconomists have mounted a convincing argument that these new drugs are really a bargain in the long run-reducing expensive hospitalizations, especially admissions to cardiac intensive care units after near lethal overdoses, and minimizing lost work days. For such claims to warrant any merit, however, there needs to be firm evidence that the new agents are at least as effective in clinical practice as the previous generation of antidepressants.
Drs Joffe and Sokolov, with noted expertise in the field of depression research, and Dr Streiner, with expertise in statistical methodology, have combined their respective academic strengths to respond to 2 previous reports, those of Greenberg and others (1) and Song and others (2) , which brought into question the effect size of antidepressant treatment response and the evidence that SSRIs should be considered "first-line" medications.
In their response, Joffe and colleagues have again turned to the randomized control trial literature to calculate the effect size of antidepressant response. Rigorous inclusion criteria, in particular the requirement that 3 comparison groups be involved in each study (that is, a new drug versus an active comparator versus placebo), excluded many other trials. The age criterion of 18 to 70 years also had the potential to include some, but not all, trials involving depressed geriatric patients. Although 92 studies met the original inclusion criteria, 42 were excluded because they "did not provide response measures that could be extracted in a form suitable for analysis" (p 614). The authors do not provide further details as to why almost half of the studies were excluded.
In reaching their conclusion that the effect sizes "for antidepressant treatment are moderately large when compared with placebo" and the effect size "for the TCAs was nonsignificantly larger than for SSRIs" (p 615), the authors have reduced their regression equation to 3 predictors: duration of the trial, drug class (TCA versus SSRI only), and whether or not objective diagnostic criteria were cited. Diagnostic criteria proved more significant in this analysis than duration of trial or drug class. This analysis excludes drugs from the other categories (for example, phenelzine, venlafaxine, moclobemide), however, which reduces their sample size of studies substantially.
The metaanalysis performed by Joffe and others was also limited by the fact that most studies they reviewed did not provide standard deviations of baseline scores (the denominator in the effect size equation). Thus they employed "a conservative estimate" "taken from the literature" (p 614). No information is provided about how this "conservative estimate" was derived. A more detailed account of the figures upon which they derived their estimate would have improved confidence in their results.
It would also have been useful to have had sample sizes for each of the studies used in the review, or at least indications that no one drug consistently had larger sample sizes than another drug. This is important because the formula used in calculating the effect sizes weighted sample size; thus, unless sample size was equally distributed across drug type, larger or smaller effects could be attributed to sample size rather than drug efficacy alone.
Joffe and others have made an important contribution to the antidepressant "efficacy of treatment" debate. Still, unanswered questions concerning "effectiveness of treatment" remain. Efficacy studies, upon which Joffe and others relied for their metaanalysis, employ methodologies wherein patients are randomly assigned to different conditions and in which considerable control is exerted over the nature and duration of treatment. Effectiveness studies are characterized by observations of patients "in the field" who have been free to choose or pursue whatever treatment they prefer, and the nature of the treatment is left uncontrolled. Efficacy studies offer the best internal but the weakest external validity; effectiveness studies, while experimentally uncontrolled, address more directly the issue of treatment in the real world of clinical practice. We would argue that what is equally if not more important than the efficacy of treatment, especially to clinicians, is the effectiveness of treatment.
Another limitation of efficacy studies or metaanalyses that rely on them is that while they can provide empirical validation of certain medications in treating index episodes, they cannot very well address critical issues of reoccurrence. It is ethically questionable, for example, whether patients can be randomly assigned to a placebo condition for the many months or even years that long-term treatment takes (3) .
Effectiveness methodologies, such as consumer satisfaction and pharmacoeconomical studies, have enhanced external validity but are also not without their weaknesses. They usually fail to capture information about individual diagnostic categories or standard outcome measures, and nonrandom assignment makes it impossible to assign specific treatment effects. Ultimately, the solution to the dilemma surrounding the advantages and disadvantages of efficacy and effectiveness studies may lie in practice-based pharmacoepidemiological research. Pharmacoepidemiological methods provide the opportunity to observe not only how medications are prescribed but also whether drugs are as effective and safe in a clinical setting as they appear to have been under randomized control trial conditions. These reservations notwithstanding, this paper is a significant contribution to this crucial area of psychiatry.
